

- Cystoscopy, 60e-4, 587
- Cytarabine  
action of, 682  
adverse effects of, 380, 607t, 682–683, 2686t  
for AML, 682–683, 684  
for neoplastic meningitis, 1793  
for primary central nervous system lymphoma, 602
- Cytidine deaminase, 103e-23
- Cytoadherence, 1371
- Cytochrome b5 (CYB5A), 2353
- Cytochrome b5 reductase deficiency, 654t
- Cytochrome c, 102e-8–9
- Cytochrome c oxidase deficiency, 85e-3–4, 85e-5f, 85e-7
- Cytochrome oxidase inhibitors, 473e-11t
- Cytochrome P450 monooxygenase, 33
- Cytogenetic analysis  
molecular, 83e-2, 83e-2f. *See also* Fluorescence in situ hybridization (FISH)  
postnatal indications for, 83e-4t  
prenatal indications for, 83e-3–4, 83e-4t  
standard, 83e-1, 83e-1f
- Cytogenomic analysis  
comparative genomic hybridization, 83e-3, 83e-3t  
indications for, 83e-3–4, 83e-4t  
SNP array, 83e-2f, 83e-3, 83e-3t. *See also* Single-nucleotide polymorphisms (SNPs)
- Cytokeratins  
in carcinoma of unknown primary, 120e-1, 120e-2, 120e-2f, 120e-2t  
in lung cancer, 508
- Cytokine(s), 372e-9  
in asthma, 1673–1674  
in atherosclerosis, 291e-2  
in autoimmune and inflammatory diseases, 372e-25t, 372e-27t, 372e-30  
biologic activity of, 372e-10–13t  
definition of, 372e-1  
expression of, 2114–2115  
of innate immune system, 372e-2, 372e-4t  
production in CNS, 125  
proinflammatory  
in anemia, 630, 630f  
in asthma, 1673–1674  
cellular signaling pathways for, 145e-5, 145e-6f  
in HIV infection, 1234–1235  
in host response to pathogens, 145e-10, 372e-26  
in metabolic syndrome, 2452  
pyrogenic, 124–125, 125f  
receptors of, 372e-10–13t  
secretion of, 372e-14f  
in sepsis/septic shock, 1753  
signaling deficiency, in SCID, 2108  
sources and targets of, 372e-10–13t  
structural families of, 372e-14t  
in thyroid-associated ophthalmopathy, 2294  
in thyroid hormone synthesis, 2285
- Cytokine blockers, 377e-5
- Cytokine receptor–linked kinase, 400e-1t
- Cytokine receptors, 372e-15–16, 400e-3–4, 400e-3f. *See also specific receptors*
- Cytokine release syndrome, 1796
- Cytokine storm, 956
- Cytokine therapy, 103e-22, 487, 492
- Cytomegalovirus (CMV), 214e-4, 214e-9, 1190
- Cytomegalovirus (CMV) immune globulin, 1193
- Cytomegalovirus (CMV) infections, 1190  
in burn patient, 166e-3  
in cancer patient, 489, 489t, 492  
congenital, 50, 1191, 1191t  
diagnosis of, 150e-7–8, 1192–1193  
diarrhea in, 266  
differential diagnosis of, 1190t  
epidemiology of, 1190–1191  
esophagitis, 1896f, 1910  
graft-versus-host disease and, 921–922  
in HIV infection, 1191t, 1192, 1252t, 1257, 1267  
in liver allograft, 366e-3f  
in lung allograft, 320e-4  
lymphadenopathy in, 408  
mononucleosis, 1191–1192  
nausea and vomiting in, 258  
neuropathy in, 2685  
pathogenesis of, 1191  
pathology of, 1191  
perinatal, 1191  
pharyngitis, 231  
pneumonia, 1192  
in pregnancy, 50  
prevention of, 1193  
proctitis, vs. IBD, 1956  
retinitis  
clinical features of, 1192, 1192f  
in HIV infection, 1267  
treatment of, 215e-7, 215e-8, 1193  
skin manifestations of, 362, 362t  
transfusion-transmitted, 138e-6, 1193  
in transplant recipient  
after heart transplant, 926  
after HSCT, 920t, 921–922, 921t, 1191t  
after kidney transplant, 925–926  
after lung transplant, 927  
clinical features of, 1191t, 1192  
herpesviruses and, 927  
pathophysiology of, 921, 926  
prevention of, 1191t  
prophylaxis for, 139e-4, 139e-4t, 215e-8, 1831  
sites of, 924t  
treatment of, 320e-4, 922, 926, 1191t, 1831  
treatment of, 215e-2t, 215e-7–9, 1193–1194, 2657
- Cytoplasmic antineutrophil cytoplasmic antibody (c-ANCA), 377e-4, 2180
- Cytosine, 429, 431f
- Cytosine arabinoside, 103e-11t, 103e-14, 103e-25, 620t, 649
- Cytoskeletal proteins, 1553, 1555t, 1556f
- Cytotoxic edema, 1777
- D**
- d4T (stavudine), 1273, 1276f, 1279f
- Dabigatran  
adverse effects of, 757, 1488  
dosage of, 757  
drug interactions of, 42  
for DVT/PE, 1635  
indications for, 379, 756–757  
management before endoscopic procedures, 1889t  
monitoring treatment with, 407, 757  
pharmacology of, 756t  
in pregnancy, 757  
for stroke prevention in atrial fibrillation/atrial flutter, 1485t, 1488, 2570  
for VTE prophylaxis, 1637t
- Dabrafenib  
action and targets of, 102e-5t, 103e-16f, 103e-17t, 103e-19  
adverse effects of, 103e-17t  
for melanoma, 103e-17t, 103e-19, 498, 499
- Dacarbazine (DTIC)  
action of, 103e-12  
adverse effects of, 103e-9t, 103e-12, 103e-25, 389t, 474, 607t  
for malignant pheochromocytoma, 2331  
for melanoma, 499  
for soft tissue sarcoma, 119e-2
- Daclatasvir, 2049
- Daclizumab, 1517
- Dacryocystitis, 199
- Dacryocytes, 81e-1
- Dactinomycin  
adverse effects of, 103e-9t  
for Ewing's sarcoma, 119e-4  
for gestational trophoblastic disease, 124e-5, 597
- Dactylitis  
characteristics of, 829, 2176f, 2220  
etiologic of, 829, 2220  
in psoriatic arthritis, 2176, 2176f  
in reactive arthritis, 2174  
in sickle cell disease, 2242
- DADs (delayed afterdepolarizations), 273e-3, 273e-3f
- Dakin's solution, 262e-4
- Dalbavancin  
action of, 930, 931t, 961  
adverse effects of, 938t, 942  
indications for, 940t, 942  
in pregnancy and lactation, 937t  
resistance to, 931t, 933–934  
for staphylococcal infections, 961, 962t
- Dalfampridine, 2672
- Dalfopristin. *See* Quinupristin-dalfopristin
- Dalteparin, 1635t, 1637t
- DALY (disability-adjusted life years), 9, 10f, 11t
- Damage-associated molecular patterns (DAMPs), 145e-8f, 377e-2, 1747, 2227f
- Damocles syndrome, 475
- Danaparoid, 728
- Danazol, 225e-5, 727t
- Dandruff, 1357
- Danon's disease (LAMP2 deficiency), 432e-4t, 433e-5, 1566
- Dantrolene, 2660, 2672
- Dapagliflozin, 2414t
- Dapsone  
for acne vulgaris, 352  
adverse effects of  
frequent, 246e-4t  
in G6PD deficiency, 656, 656t, 1126, 1262  
hemolysis, 373  
hypersensitivity, 382. *See also* Drug-induced hypersensitivity syndrome (DIHS)  
methemoglobinemia, 373, 1384  
neuropathy, 2687t  
occasional, 246e-4t, 1126  
for dermatitis herpetiformis, 373  
drug interactions of, 246e-4t  
for epidermolysis bullosa acquisita, 374  
for leprosy, 1126–1127, 1127t  
for linear IgA disease, 373  
for lupus dermatitis, 2134  
for mucous membrane pemphigoid, 374  
overdosage/poisoning with, 473e-11t  
for PCR, 1362t  
for PCP prophylaxis, 1251t, 1362t  
in pregnancy and lactation, 246e-4t  
for relapsing polychondritis, 2204  
for toxoplasmosis prophylaxis in HIV infection, 1251t
- Daptomycin  
action of, 931t, 932f, 933, 961  
adverse effects of, 938t, 942, 976  
for enterococcal infections, 975t, 976  
indications for, 940t, 942  
for infective endocarditis, 823  
for MRSA infections, 962t, 963  
for osteomyelitis, 840t  
resistance to, 931t, 934, 940t, 961  
for staphylococcal infections, 961, 962t
- Darbepoetin alfa, 631
- DARC receptor, 1240t
- Darier's sign, 367, 2120
- Darifenacin, 81
- Darmbrand (enteritis necroticans), 991
- Dartmouth Atlas of Health Care, 12e-3
- Darunavir  
adverse effects of, 1275t, 1281  
for HIV infection, 1275t, 1276f, 1280–1281  
resistance to, 1280f
- DAS181, for influenza, 215e-6
- Dasatinib  
action and targets of, 102e-3, 102e-5t, 103e-16, 103e-17t  
adverse effects of, 103e-17t, 103e-26, 692  
for CML, 102e-3, 102e-5t, 691–692, 691t  
genetic variations in response to, 39t, 103e-16
- DASH diet, 1622t, 1623
- Daunorubicin  
action of, 103e-13  
adverse effects of, 103e-10t, 103e-13, 354, 379  
for AML, 682, 683  
drug interactions of, 103e-10t  
liposomal, for Kaposi's sarcoma, 1270  
David procedure, 1538f